- Home
- General Medicine
- Clinical Outcomes from the ALLEGRO Trial of Ritlecitinib in Alopecia Areata
9mo3 min read
Medical Article
Introduction: Alopecia Areata (AA) is an autoimmune disease possessing immunoinflammatory mechanisms that lead to hair loss from the scalp, face, and/or body (1). Among affected patients, approximately 10-35% experience progression to more severe forms of AA (1). Moderate to severe AA has been refractory to treatment, although Janus Kinase inhibito

Clinical Outcomes from the ALLEGRO Trial of Ritlecitinib in Alopecia Areata
766 Reached
Similar Content

Woman presented with Fever of Unknown Origin
7739 Reached93 Comments19 Likes

How Physicians Should Manage Stress?
35340 Reached151 Comments202 Likes

Rubella Syndrome in Neonate
1402 Reached12 Comments9 Likes

Pregnant Woman with HIV-1 Infection
747 Reached1 Likes

Black Lesion in Old Female
1974 Reached5 Comments11 Likes
